Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

EGFR-TKIs Combine Chemotherapy as First-line Therapy for Patients With Advanced EGFR Mutation-positive NSCLC

NCT02886195 is registered in ClinicalTrials.gov with Fujian Cancer Hospital as lead sponsor.

NCT NCT02886195
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02886195 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
EGFR-TKIs Combine Chemotherapy as First-line Therapy for Patients With Advanced EGFR Mutation-positive NSCLC
Lead sponsor
Fujian Cancer Hospital
Phase
Phase 3
Overall status
Unknown status
Start date
July 31, 2016
Completion date
July 31, 2019
Enrollment
120 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

egfr gene mutation